Development of Unilateral Cervical and Supraclavicular Lymphadenopathy After Human Papilloma Virus Vaccination

Studdiford, James; Lamb, Kathleen M.; Horvath, K; Altshuler, Marc; Stonehouse, Amber

doi:10.1592/phco.28.9.1194

Cited by 69 publications

(47 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We reviewed the current literature and found a single case report of lymphadenopathy after HPV vaccination, described in a 26-year-old woman. We did not find any reports of post-HPV 9-valent vaccination lymphadenopathy in children 12…”

Section: Introductioncontrasting

confidence: 70%

Neck and supraclavicular lymphadenopathy secondary to 9-valent human papillomavirus vaccination

2019

View full text Add to dashboard Cite

We present two clinical cases of lymphadenopathy after vaccination with the human papillomavirus (HPV) 9-valent vaccine: an asymptomatic 11-year-old boy with inferior cervical and supraclavicular lymphadenopathy, and a 13-year-old girl who presented with lymphadenopathy. In both cases, medical history was unremarkable and there was no recent infection, or other clinical findings. Both adolescents had received the HPV 9-valent vaccine in the previous week. In the first case, blood tests, ultrasonography and biopsy were performed, while in the second, a watchful waiting strategy was adopted. In both cases, the lymphadenopathy resolved spontaneously. The boy received the second dose of the vaccine 6 months later and lymphadenopathy reappeared. The Naranjo scale was applied, classifying the events as definite (in the case of the boy) and probable (girl) adverse drug reactions. The vaccine is safe, but recognising this minor adverse event is important to prevent unnecessary investigation and reduce patient and parental anxiety.

show abstract

Section: Introductioncontrasting

confidence: 70%

Neck and supraclavicular lymphadenopathy secondary to 9-valent human papillomavirus vaccination

2019

View full text Add to dashboard Cite

show abstract

“…Lymphadenopathy of the arm and neck was among the unsolicited side effects in the FDA's report with 64 cases; however, it should have been a predictable side effect due to it being common with other vaccines such as the human papillomavirus vaccine and influenza vaccine [35][36][37] Therefore, in this study, lymphadenopathy was among the general side effects of the COVID-19 vaccine and its overall prevalence was 16.2%, with a higher frequency among females compared to males (16.8% vs. 10.6%), young adults compared to old adults (17.3% vs. 15.1%), and people with allergies (21.4% vs. 14.5%), asthma (17.6% vs. 14.1%), bowel disease (25% vs. 14.3%), cardiac disease (25% vs. 14.2%), COPD (20% vs. 14.8%), DM type-2 (19% vs. 14.5%), and neurologic disease (30% vs. 14.2%). The majority of participants with lymphadenopathy reported that its duration was either one day (18.9%), three days (43.9%), or five days (18.2%).…”

Section: Discussionmentioning

confidence: 99%

Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic

Riad

Pokorná

Attia

et al. 2021

JCM

335

333

View full text Add to dashboard Cite

Background: COVID-19 vaccine side effects have a fundamental role in public confidence in the vaccine and its uptake process. Thus far, the evidence on vaccine safety has exclusively been obtained from the manufacturer-sponsored studies; therefore, this study was designed to provide independent evidence on Pfizer–BioNTech COVID-19 vaccine side effects. Methods: A cross-sectional survey-based study was carried out between January and February 2021 to collect data on the side effects following the COVID-19 vaccine among healthcare workers in the Czech Republic. The study used a validated questionnaire with twenty-eight multiple-choice items covering the participants’ demographic data, medical anamneses, COVID-19-related anamneses, general, oral, and skin-related side effects. Results: Injection site pain (89.8%), fatigue (62.2%), headache (45.6%), muscle pain (37.1%), and chills (33.9%) were the most commonly reported side effects. All the general side effects were more prevalent among the ≤43-year-old group, and their duration was mainly one day (45.1%) or three days (35.8%) following the vaccine. Antihistamines were the most common drugs associated with side effects, thus requiring further investigation. The people with two doses were generally associated with a higher frequency of side effects. Conclusions: The distribution of side effects among Czech healthcare workers was highly consistent with the manufacturer’s data, especially in terms of their association with the younger age group and the second dose. The overall prevalence of some local and systemic side effects was higher than the manufacturer’s report. Further independent studies on vaccine safety are strongly required to strengthen public confidence in the vaccine.

show abstract

“…Based on former experiences, H1N1 Influenza, smallpox, measles, Bacille Calmette-Guerin, and human papillomavirus (HPV) vaccines can cause infrequent axillary LAP ( 27 , 28 , 29 , 30 , 31 ). Several studies showed increased axillary nodal FDG uptakes following H1N1 influenza vaccination in the FDG PET/CT imaging.…”

Section: Discussionmentioning

confidence: 99%

Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review

et al. 2021

View full text Add to dashboard Cite

Rationale and objectives : Despite all the benefits and effectiveness of the coronavirus disease 2019 (COVID-19) vaccines mentioned in recent clinical trials, some post-vaccination side effects such as lymphadenopathy (LAP) were observed. The present study reviewed all studies with imaging findings presentation of LAP after COVID-19 vaccination. Materials and methods : We conducted a literature search in online databases, including Scopus, Medline (PubMed), Web of Science, Embase (Elsevier), Cochrane library, and Google Scholar. Results : A total of 19 studies (68 cases), including 60 (88.2%) females and 8 (11.8%) males with a presentation of LAP after COVID-19 vaccination, were reviewed. LAP was identified after first or second dosages of three types of COVID-19 vaccines, including Pfizer-BioNTech (n = 30, 44.1%), Moderna (n = 17, 25%), and Oxford-AstraZeneca (n = 1, 1.5%). In 20 (29.4%) cases, vaccine type was not reported or only reported as mRNA COVID-19 vaccine. The median days of LAP presentation after the first and second dosages of COVID-19 vaccination, were 12 and 5 days, respectively. Most of the LAP imaging findings related to COVID-19 vaccination (n = 66, 97%) were seen from first day to four weeks after vaccination. However, LAP remained after 5 and 6 weeks of the first and second dosages of COVID-19 vaccination with decreased lymph nodes’ size and residual cortical thickening in two cases. Conclusion : This review study of cases with LAP-associated COVID-19 vaccination guides radiologists and physicians to rely on patient's clinical context and updated resources to prevent potential disease upstaging and change in therapy.

show abstract

Development of Unilateral Cervical and Supraclavicular Lymphadenopathy After Human Papilloma Virus Vaccination

Cited by 69 publications

References 8 publications

Neck and supraclavicular lymphadenopathy secondary to 9-valent human papillomavirus vaccination

Neck and supraclavicular lymphadenopathy secondary to 9-valent human papillomavirus vaccination

Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic

Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review

Contact Info

Product

Resources

About